Dr. James A. Scott, MD PHD.
Neurology (Diagnostic Neuroimaging (Psychiatry & Neurology) Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,090
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: University of Florida College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Diagnostic Neuroimaging (Psychiatry & Neurology) Physician primary
FL license ME058332 -
Specialist
FL license ME0058332
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Daytona Beach Daytona Beach, FL
- Adventhealth PAlm Coast Palm Coast, FL
- Halifax Health Medical Center Daytona Beach, FL
- Adventhealth New Smyrna Beach New Smyrna Beach, FL
- Halifax Health /uf Health Medical Center of Delton Deltona, FL
Medical groups
- Ability Health Services and Rehabilitation LP (1,269 clinicians)
- Ability Health Services, Inc (1,258 clinicians)
- Halifax Healthcare Systems Inc (356 clinicians)
- Neurology Associates of Ormond Beach PA (8 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,090
- Services billed
- 3,434
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,463 | 681 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 768 | 236 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 255 | 236 |
| Measurement of brain wave activity (eeg), awake and asleep | 239 | 216 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 197 | 109 |
| New patient office or other outpatient visit, 60-74 minutes | 158 | 158 |
| Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth | 113 | 108 |
| Nerve conduction, 7-8 studies | 49 | 47 |
| Nerve conduction, 3-4 studies | 36 | 36 |
| Nerve conduction, 5-6 studies | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Ormond Beach, FL | 547 |
| Donepezil Hcl Other prescribers in Ormond Beach, FL | 409 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Ormond Beach, FL | 321 |
| Ropinirole Hcl Other prescribers in Ormond Beach, FL | 234 |
| Topiramate Other prescribers in Ormond Beach, FL | 233 |
| Levetiracetam Other prescribers in Ormond Beach, FL | 216 |
| Duloxetine Hcl Other prescribers in Ormond Beach, FL | 211 |
| Clonazepam Other prescribers in Ormond Beach, FL | 180 |
| Pregabalin Other prescribers in Ormond Beach, FL | 167 |
| Memantine Hcl Er (memantine hcl) Other prescribers in Ormond Beach, FL | 165 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 32 companies reported 170 payments worth $4,346 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $789 |
|---|---|
| AbbVie Inc. | $435 |
| Pfizer Inc. | $295 |
| Eisai Inc. | $269 |
| Argenx US, Inc. | $223 |
| Biogen, Inc. | $219 |
| Vanda Pharmaceuticals Inc. | $207 |
| Amgen Inc. | $185 |
| Food and Beverage | $4,001 |
|---|---|
| Travel and Lodging | $280 |
| Education | $64.43 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Feb 19, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $280 |
| Amgen Inc. Apr 8, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $28.63 |
| Janssen Pharmaceuticals, Inc Oct 8, 2025 | Education in-kind | $17.90 |
| Janssen Pharmaceuticals, Inc Jul 11, 2025 | Education in-kind | $17.90 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $849,806 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
Novartis Pharmaceuticals Corporation - An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
Novartis Pharmaceuticals Corporation - CCYB704A12301
Hexal AG - A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Novartis Pharmaceuticals Corporation - A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.